Abstract
A double-blind trial of MS-Antigen was carried out in one hundred cases of nasal allergy. The effect of MS-Antigen was compared with that of the active placebo-d-chlorpheniramige maleate. MS-Antigen was discovered as a new therapeutic agent by M. Soeda in 1965. Treatment with
40 mg daily of MS-Antigen (20mg for under 15 years old) or with 12mg daily of d-chlorpheniramine maleate was continued for 4 weeks. Characteristic nasal symptoms, such as sneezing, nasal obstruction, nasal discharge and rhinoscopic findings were observed, while the other necessary clinical investigations were made before, during and after the administration of the drugs. A global judgement was made at the end of the therapy and 4 weeks after the ceasing of the treatment.
The effect of both drugs wese compared by the sequential method, but we didn't find any difference between MS-Antigen and active placebo. However, on the global judgement at the time of 8 weeks (4 weeks after the ceasation of the drugs), the success-rates were higher in MS-Antigen (77%) than in active placebo (59%). The difference was statistically significant (P<0.05).
The side-effect of MS-Antigen was rare and not serious.
